A Comprehensive Software Ecosystem for End-to-End Monoclonal Antibody and Antibody–Drug Conjugate Data Acquisition, Analysis, and Reporting

Importance of the topic

Large biotherapeutics such as monoclonal antibodies (mAbs) and antibody–drug conjugates (ADCs) are structurally complex and carry multiple critical quality attributes (CQAs) that determine safety and efficacy. Reliable, end-to-end analytical workflows — from automated data acquisition to standardised analysis and reporting — are essential for process development, quality control, and regulatory submissions. Integrated software ecosystems that connect instruments, methods, data-processing pipelines, and reporting templates reduce manual work, increase reproducibility, and help ensure compliance across multiuser laboratory environments.

Objectives and study overview

The work describes the development and demonstration of a complete software platform for automated acquisition, analysis, and reporting of mAb and ADC data at multiple structural levels: intact protein, native mass spectrometry (MS), denatured intact/DAR (drug-to-antibody ratio) evaluation, and peptide mapping. Proof-of-concept evaluations used trastuzumab (Herceptin), trastuzumab emtansine (T-DM1), and the NISTmAb to benchmark performance, robustness, and the capability to run unattended multi-day sequences with predefined analysis and reporting methods.

Methodology and instrumentation used

The study combined liquid chromatography (size-exclusion, reversed-phase, and polymeric reversed-phase) with high-resolution time-of-flight MS. Key analytical approaches included:

• Intact and native MS analysis for molecular mass and DAR assessment.
• Denaturing reversed-phase LC–MS for intact mass and glycoform profiling.
• Trypsin digestion and peptide mapping for sequence coverage and site-specific characterization, including MS/MS fragmentation for peptide identification.
• Automated sequences with task and wait actions and sample-specific custom parameters to enable multi-day unattended operation, immediate post-acquisition processing, and automated report generation.

Used instrumentation

Instrumentation and software components reported or evaluated in the work include:

• Agilent LC systems with Altura Ultra Inert and Altura column chemistries (SEC 200Å, PLRP-S 1000Å, ZORBAX Eclipse Plus C18).
• Agilent TOF MS platforms (6230C TOF LC/MS; additional measurements reported on 6545XT and a Revident instrument for peptide mapping comparisons).
• OpenLab CDS and MassHunter software suites for instrument control and data acquisition, with BioConfirm modules for automated data analysis (DAR calculation, modification profiling, sequence matching) and built-in report templates.
• Standard LC/MS consumables: LC–MS grade solvents (acetonitrile, water, formic acid), solvent inlet filters, quick-connect fittings, polypropylene vials and snap-top caps.

Main results and discussion

The platform demonstrated robust performance across multiple evaluation metrics:

• Intact and DAR analysis: Both native and denaturing conditions produced accurate intact mass profiles for trastuzumab and precise DAR determination for T-DM1 when using the Altura Ultra Inert columns coupled with the 6230C TOF system.
• Peptide mapping: Trypsin-digested trastuzumab achieved high sequence coverage (reported ~88.9% on Revident and 91.0% on 6545XT), and representative peptides exhibited clear MS/MS fragment coverage supporting confident identification.
• Automation and throughput: Sequences were configured to run unattended for multiple days; the system executed instrument actions (power cycling LC modules, MS calibration), injections, and automated post-acquisition processing and reporting without manual intervention.
• Reproducibility and robustness: Overlaid total ion chromatograms across 75 injections spanning three days showed minimal retention time shifts; glycoform quantitation across 75 replicates for Herceptin and NISTmAb exhibited high reproducibility, indicating stable chromatography and consistent MS response.
• Reporting: Built-in and customizable report templates supported intact protein, DAR, peptide digest, and released glycan reporting, enabling automated generation of regulatory-ready output.

Benefits and practical applications of the method

The integrated ecosystem offers several practical advantages for biopharmaceutical analysis:

• End-to-end automation reduces hands-on time and human error, increasing laboratory throughput and consistency for routine QC and R&D workflows.
• Centralised client–server architecture allows multiuser sharing of methods, analysis workflows, and reporting templates, supporting standardisation and change control for regulated environments.
• Modular data-analysis modules (e.g., BioConfirm) enable targeted CQA monitoring (DAR, glycoforms, sequence variants, PTMs) and facilitate rapid review and decision-making.
• Compatibility with both native and denaturing workflows makes the solution versatile for structural characterization, stability studies, and formulation screening.

Future trends and potential uses

Key directions and opportunities for expanding such an ecosystem include:

• Increased automation and closed-loop control linking analytical outcomes to downstream decision-making (e.g., automated acceptance/rejection or adaptive reanalysis strategies).
• Integration with laboratory information management systems (LIMS) and electronic quality systems to streamline release testing and regulatory reporting.
• Enhanced informatics: machine-learning assisted peak annotation, PTM localization, and anomaly detection to accelerate interpretation of complex charge/isoform profiles.
• Expansion to hybrid workflows combining orthogonal techniques (CE–MS, ion mobility MS) to deepen structural insights for next-generation biotherapeutics.

Conclusion

The demonstrated software and hardware combination provides a comprehensive, robust solution for mAb and ADC characterization across intact, native, and peptide levels. It supports unattended multi-day operation, high reproducibility, accurate DAR and glycoform quantitation, and automated report generation. The platform’s modularity and centralised management make it well suited for both R&D and regulated QC environments, reducing manual workload while improving data consistency and traceability.

References

• Luo R., Li G., Xiu L., Hsiao J., Wu L., Wong D. A Comprehensive Software Ecosystem for End-to-End Monoclonal Antibody and Antibody–Drug Conjugate Data Acquisition, Analysis, and Reporting. ASMS 2026, TP 297. Agilent Technologies, Santa Clara, CA. DE-014666.
• Instrument and consumable details as reported by Agilent Technologies: Altura Ultra Inert columns (SEC 200Å, PLRP-S 1000Å, ZORBAX Eclipse Plus C18), Agilent 6230C and 6545XT TOF LC/MS platforms, OpenLab CDS, MassHunter, BioConfirm analysis modules.